Review Timeline | CrossMark Policy | ClinMed Features
logo
International Journal of
Immunology and Immunotherapy ISSN: 2378-3672

Citation

Ezekwudo D, Keidan R, Gbadamosi B, Douglas-Nikitin VK, Yu Z, et al. (2018) Durable Response with the Anti-Pd-L1 Monoclonal Antibody Avelumab in Non-Resectable Advanced Merkel Cell Carcinoma: Review of Literature. Int J Immunol Immunother 5:030. doi.org/10.23937/2378-3672/1410030

Copyright

© 2018 Ezekwudo D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CASE REPORT | OPEN ACCESS DOI: 10.23937/2378-3672/1410030

Durable Response with the Anti-Pd-L1 Monoclonal Antibody Avelumab in Non-Resectable Advanced Merkel Cell Carcinoma: Review of Literature

Daniel Ezekwudo1*, Richard Keidan2, Bolanle Gbadamosi1, Vonda K Douglas-Nikitin3, Zhou Yu1, Jeffrey Margolis1, Michael Stender1, Susanna Gaikazian1 and Ishmael Jaiyesimi1

1Department of Hematology and Oncology, Oakland University William Beaumont School of Medicine, USA

2Department of General Surgery, Oakland University William Beaumont School of Medicine, USA

3Department of Clinical Pathology, Oakland University William Beaumont School of Medicine, USA

Abstract

Introduction

Merkel cell carcinoma (MCC) is an aggressive form of skin cancer typically associated with a poor prognostic outcome.

Case description

A case of non-resectable, advanced Merkel cell carcinoma of the right pelvis and right inguinal region in a 67-year-old man was treated with the anti PD-L1 monoclonal antibody avelumab and Radiation therapy, with maintenance of a durable response 24 months later. The rare presentation of this aggressive form of skin cancer and its clinicopathologic features are presented.

Conclusions

Up-to-date information on the clinical management of MCC, including the utilization of human anti-PD-L1 monoclonal antibody, and ongoing clinical trials in both localized and metastatic settings of MCC are discussed.